FilingReader Intelligence
Wantai Bio continues cash management with idle funds
June 11, 2025 at 11:53 PM UTC•By FilingReader AI
Beijing Wantai Biological Pharmacy Enterprise (SSE:603392) announced the redemption of a CNY50 million structured deposit product that matured on June 6, 2025, yielding CNY585,900 in earnings. The company's board has authorized the continued use of idle funds raised from a non-public stock offering for cash management, with a maximum investment of CNY1.5 billion in low-risk, liquid products.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:603392•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Beijing Wantai Biological Pharmacy Enterprise publishes news
Free account required • Unsubscribe anytime